NRx submits 70,000-patient ketamine data to US FDA
The Future of Mental Health Treatment: Real-World Evidence and the Rise of Ketamine The landscape of mental healthcare is undergoing a significant shift, driven by a growing acceptance of innovative treatments and a powerful new tool: real-world evidence (RWE). Recent developments surrounding NRx Pharmaceuticals (Nasdaq: NRXP) and its pursuit of FDA approval for NRX-100, a … Read more